Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
Details : SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss, aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 demonstrated a statistically significant effect with the high dose on pure tone audiometry (≥ 10 decibels improvement vs placebo) in Phase 2 AUDIBLE-S trial in SSNHL at Day 84 in per protocol idiopathic population (81 patients) treated with co...
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Association for Research in Otolaryngology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (R-azasetron besylate), oral small molecule lead asset currently being investigated in sudden sensorineural hearing loss and cisplatin-induced ototoxicity aims to protect and preserve inner ear tissue from damage.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Association for Research in Otolaryngology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Cochlear Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022
Details : SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Cochlear Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021
Details : The poster presented shows SENS-401 ability to yield significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma.
Product Name : SENS-401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2021
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azasetron
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment
Details : Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Azasetron
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable